1. Home
  2. CTW vs NKTX Comparison

CTW vs NKTX Comparison

Compare CTW & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CTW

CTW Cayman Class A Ordinary Shares

HOLD

Current Price

$2.58

Market Cap

171.6M

Sector

Technology

ML Signal

HOLD

Logo Nkarta Inc.

NKTX

Nkarta Inc.

HOLD

Current Price

$2.86

Market Cap

198.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTW
NKTX
Founded
2013
2015
Country
Japan
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
171.6M
198.2M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
CTW
NKTX
Price
$2.58
$2.86
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$11.33
AVG Volume (30 Days)
13.2K
486.9K
Earning Date
05-13-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
11.88
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$22.41
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.10
$1.63
52 Week High
$3.14
$3.65

Technical Indicators

Market Signals
Indicator
CTW
NKTX
Relative Strength Index (RSI) 45.73 52.26
Support Level $1.92 $2.59
Resistance Level $2.56 $3.34
Average True Range (ATR) 0.28 0.22
MACD 0.02 -0.00
Stochastic Oscillator 34.83 60.00

Price Performance

Historical Comparison
CTW
NKTX

About CTW CTW Cayman Class A Ordinary Shares

CTW Cayman operates the web-based HTML5 gaming platform G123.jp, offering free-to-play games based on Japanese animations, including Queen's Blade, So I'm a Spider, So What?, and Goblin Slayer. The platform features 29 games, with 11 in pre-registration. The Group provides a platform for game developers to generate revenue and reach an international audience through shared revenue from players' in-game purchases. It operates in Japan, Singapore, Taiwan, and China, excluding Taiwan, with the majority of revenue derived from Japan, and has one reporting segment focused on game distribution and related services.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: